A patient came to my office recently and told me she had stopped her statin. She’d been on it for two years. Her coronary artery calcium score was 280 and LDL was 168, up almost 100 points since she had stopped taking her statin. Her father had died from a heart attack at 58.
When I asked about the decision, she crossed her arms and furrowed her brow.
She stopped the statin because she felt “foggy and maybe a little achy,” she said, and things she read online suggested the statin was to blame.
She was, however, continuing to inject BPC-157 — a synthetic peptide she’d ordered from a website that labeled it “for research use only” — into her thigh three times a week for a knee injury. She heard about it on a podcast and then did some research. When I asked her about BPC, not only did the aforementioned arms uncross, but her face lit up.
My patient is intelligent, motivated, and doing what she believes is best for her body. She also represents a pattern I now see weekly in my practice, and it reveals something more alarming than any individual treatment decision: In consumer health culture, the volume of evidence behind a therapy has become inversely correlated with public trust in it.
The Lancet published a study in February that should have closed the book on statin side effects. The Cholesterol Treatment Trialists’ Collaboration analyzed individual data from 19 double-blind randomized trials — 123,940 people, followed for a median of 4.5 years. Of the 66 adverse effects listed on statin product labels, 62 were unsupported by the trial evidence. Statins did not cause memory loss, depression, sleep disturbance, erectile dysfunction, fatigue, headache, or peripheral neuropathy. The confirmed harms were a small increase in liver enzymes, a roughly 1% incidence of muscle symptoms, and a modest rise in blood sugar in patients already near the diabetes threshold. That’s it. From 123,940 people.
This result matters because statins remain one of the most refused medications in clinical practice. Meta-analyses encompassing more than 170,000 participants have demonstrated a 25% reduction in major adverse cardiovascular events and significant reductions in all-cause mortality. A 2025 adherence meta-analysis of 3.3 million patients found that good vs. poor statin adherence reduced mortality by 35% — and that discontinuation increased mortality risk by 90%. The SAMSON trial revealed that 90% of the symptom burden patients attribute to statins is identically reproduced by placebo.
My patient’s brain fog was almost certainly not caused by her statin and neither was her achiness — her muscle enzymes were normal. But no amount of evidence could compete with the certainty she’d built from Reddit threads and podcasts.
Now consider what she replaced it with.
BPC-157 — body protection compound 157 — is a synthetic peptide derived from a protein found in gastric juice. It has generated impressive preclinical data in rodent models of tissue repair. The total human evidence base, as of this writing, consists of the following: 1) a Phase I safety trial of 42 healthy volunteers that was registered in 2015, canceled in 2016, and never published, 2) a retrospective case series of 12 patients with knee pain, no control group, and no validated outcome measure, and 3) a 2025 pilot safety study involving two healthy adults who received intravenous infusions at a single private clinic in Florida.
That is a whopping 14 humans total. That would not meet the evidentiary threshold for a poster presentation at most medical conferences. The FDA has not approved BPC-157 for any human use. It classifies the compound as Category 2 — indicating significant safety concerns when used in compounding. The World Anti-Doping Agency prohibits it for athletes. The Department of Defense prohibits its use by members of the military. There are no human dosing protocols, no long-term safety data, and no way to verify the purity or composition of what arrives in the mail when you order it from a website that exists in a regulatory vacuum.
Countless Americans are injecting it anyway.
I am not reflexively opposed to peptide therapy. I am an emergency medicine physician who also runs a practice centered on prevention, metabolic optimization, and longevity — exactly the kind of medicine that takes these biological tools seriously. If BPC-157 demonstrates efficacy and safety in properly designed human trials, I would be among the first to incorporate it. That is how this is supposed to work.
But what is happening right now is not the adoption of a promising therapy. It is the wholesale substitution of consumer enthusiasm for clinical evidence. My patient is refusing a drug studied in 170,000 people because of side effects that a 124,000-person analysis just confirmed do not exist — while injecting a compound studied in 14 humans, from unregulated sources, based on the recommendation of someone who profits from selling it. She’s probably not the only one. And those using it believe they are “doing their own research.”
The standard response from the wellness industry is that the absence of evidence is not evidence of absence — that these compounds simply haven’t been studied yet. This is technically true and profoundly misleading. The absence of evidence in this case is not an accident. BPC-157 has been around since 1992. The single clinical trial that was initiated was canceled. No pharmaceutical company, no academic medical center, and no government agency has found the existing preclinical data compelling enough to fund a rigorous human trial in over 30 years. That silence is not a conspiracy. It is a signal.
The deeper problem is epistemological. We have a population that has learned — correctly — that pharmaceutical companies have lied, that institutions have failed them, and that financial incentives distort medical recommendations. The opioid crisis alone justified a generation of skepticism.
But the response has not been better skepticism. It has been the migration of trust from one set of financially motivated actors to another. The peptide clinic charging $400 per vial for a compound with 14 human subjects studied has the same economic incentives as the pharmaceutical company charging $400 per month for a branded statin. The difference is that the pharmaceutical company was required to prove its product works before selling it.
I don’t expect to win this argument with data alone — that’s part of the problem. Trust is not rebuilt with meta-analyses. It is rebuilt in exam rooms, one patient at a time, by physicians willing to say: I understand why you don’t trust the system. I share some of those concerns. And I am asking you to consider that the compound you’re injecting three times a week has less evidence behind it than virtually any over-the-counter medication in your medicine cabinet. The statin you stopped has more. Let’s talk about what the evidence actually shows — for both.
If we can’t have that conversation, we are not practicing medicine. We are just choosing which marketing to believe.
Vikas Patel, M.D., is a board-certified emergency medicine physician, former U.S. Navy flight surgeon, and founder of MD Longevity Lab, a precision longevity medicine practice in Arlington Heights, Ill.